-
Mashup Score: 6
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18HCC screening linked to reduced mortality but remains ‘underused in clinical practice’ - 5 day(s) ago
Hepatocellular carcinoma screening in at-risk patients was linked to reduced mortality after accounting for lead-time and length-time biases, as well as improved early tumor detection and treatment, according to data in JAMA Network Open. “Although there have been several studies examining the value of HCC screening in patients with cirrhosis, there continues to be debate if this is
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2
In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Lenvatinib Is Effective, Regardless of Age in HCC - 9 day(s) ago
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
The overall value of hepatocellular carcinoma screening is defined by the balance of benefits and harms. Studies have only reported physical harms with none describing financial harms.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 84
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis. The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 83
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis. The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
Gholam Analyzes Treatment Outcomes for Advanced #HCC in Child-Pugh B Population | @cwru @pgholam @CWRUSOM @UHhospitals https://t.co/GEXgOsmJOY https://t.co/DYl1IyeEiV